CO5080761A1 - Inhibidores de lad fkbp na inhibidores de las fkbp - Google Patents
Inhibidores de lad fkbp na inhibidores de las fkbpInfo
- Publication number
- CO5080761A1 CO5080761A1 CO99045678A CO99045678A CO5080761A1 CO 5080761 A1 CO5080761 A1 CO 5080761A1 CO 99045678 A CO99045678 A CO 99045678A CO 99045678 A CO99045678 A CO 99045678A CO 5080761 A1 CO5080761 A1 CO 5080761A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- optionally substituted
- alkenyl
- cycloalkylouyl
- aryl1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Glass Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de la fórmula (I):<EMI FILE="99045678_1" ID="1" IMF=JPEG >o una sal farmacéuticamente aceptable o solvato de su entidad, en la que X es O, S, NH o N (alquilo C1-6 );R1, R2 , R3 y R4 son cada uno de ellos independientemente H, es OH, OCO(alquilo C1-6), CO2(alquilo C1-6), CONH2, CONH(alquilo C1-6), CON(alquilo C1-6)2, halógeno, cicloalquilo C3-7, oxicicloalquilo C3-7, alqueniloC2-6, arilo1, alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno y cicloalquilouilo C3-7, y alcoxi C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados entre flúor y cicloalquilouilo C3-7; A es alquileno C3-5 no ramificado, opcionalmente sustituido con hasta tres grupos alquilo C1-6; D es O o S; E es O, S, NH, N(alquilo C1-6) o CR11R12; G es alquilo C1-14 o alquenilo C2-14, cada uno de ellos opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados entre halógeno, arilo, alcoxi C1-4, cicloalquilouilo, het y NR5R6;R5 y R6 son cada uno de ellos independientemente H o alquilo C1-6 o se unen formando con el átomo de nitrógeno al que están unidos, un anillo heterocíclico de 4 a 7 eslabones, que contienen opcionalmente otro heteroradical seleccionado entre NR7, o y S(O)p, estando el anillo heterocíclico de 4 a 7 eslabones opcionalmente sustituido con hasta 3 sustituyentes independientemente seleccionados entre alquilo C1-6 y alcoxi C1-6; R7 es H, alquilo C1-6, alquenilo C2-6, COR8, S02R8, CONR9R10, CO2R8 o S02NR9R10; R8 es cicloalquilouilo C3-7, alquenilo C2-6, arilo1 o alquilo C1-6 opcionalmente sustituido con cicloalquilouilo C3-7 o arilo1; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815696.1A GB9815696D0 (en) | 1998-07-20 | 1998-07-20 | Heterocyclics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5080761A1 true CO5080761A1 (es) | 2001-09-25 |
Family
ID=10835773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99045678A CO5080761A1 (es) | 1998-07-20 | 1999-07-19 | Inhibidores de lad fkbp na inhibidores de las fkbp |
Country Status (45)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB0008939D0 (en) | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Process for preparing substituted benzimidazole compounds |
| JP2004526425A (ja) * | 2000-11-28 | 2004-09-02 | ワイス | 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析 |
| US7186518B2 (en) * | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| WO2009154754A2 (en) * | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| TWI534142B (zh) | 2011-03-15 | 2016-05-21 | 大正製藥股份有限公司 | Azole derivatives |
| EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
| CN106138044B (zh) * | 2016-07-15 | 2017-05-03 | 鲁俊东 | 一种治疗腰椎间盘突出症的药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI91859C (fi) * | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| FR2696176B1 (fr) * | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| GB9700597D0 (en) * | 1997-01-14 | 1997-03-05 | Sandoz Pharma Uk | Organic compounds |
| US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6495549B1 (en) * | 1999-07-15 | 2002-12-17 | Pfizer Inc | FKBP inhibitors |
-
1998
- 1998-07-20 GB GBGB9815696.1A patent/GB9815696D0/en not_active Ceased
-
1999
- 1999-01-07 UA UA2001010434A patent/UA60368C2/uk unknown
- 1999-06-30 HN HN1999000101A patent/HN1999000101A/es unknown
- 1999-07-01 KR KR1020017000834A patent/KR20010083130A/ko not_active Application Discontinuation
- 1999-07-01 EP EP99926683A patent/EP1098894B1/en not_active Expired - Lifetime
- 1999-07-01 CZ CZ2001224A patent/CZ2001224A3/cs unknown
- 1999-07-01 YU YU83100A patent/YU83100A/sh unknown
- 1999-07-01 ID IDW20010154A patent/ID27022A/id unknown
- 1999-07-01 PT PT99926683T patent/PT1098894E/pt unknown
- 1999-07-01 WO PCT/IB1999/001227 patent/WO2000005231A1/en not_active Application Discontinuation
- 1999-07-01 ES ES99926683T patent/ES2183567T3/es not_active Expired - Lifetime
- 1999-07-01 AP APAP/P/2001/002045A patent/AP2001002045A0/en unknown
- 1999-07-01 DK DK99926683T patent/DK1098894T3/da active
- 1999-07-01 OA OA1200100024A patent/OA11586A/en unknown
- 1999-07-01 AT AT99926683T patent/ATE225346T1/de not_active IP Right Cessation
- 1999-07-01 AU AU43855/99A patent/AU756769B2/en not_active Ceased
- 1999-07-01 SI SI9930120T patent/SI1098894T1/xx unknown
- 1999-07-01 PL PL99345705A patent/PL345705A1/xx not_active Application Discontinuation
- 1999-07-01 CN CN99810385A patent/CN1315951A/zh active Pending
- 1999-07-01 EE EEP200100043A patent/EE200100043A/xx unknown
- 1999-07-01 IL IL14024399A patent/IL140243A0/xx unknown
- 1999-07-01 CA CA002338276A patent/CA2338276C/en not_active Expired - Fee Related
- 1999-07-01 DE DE69903319T patent/DE69903319T2/de not_active Expired - Fee Related
- 1999-07-01 JP JP2000561187A patent/JP3545341B2/ja not_active Expired - Fee Related
- 1999-07-01 BR BR9912307-0A patent/BR9912307A/pt not_active Application Discontinuation
- 1999-07-01 NZ NZ508839A patent/NZ508839A/xx unknown
- 1999-07-01 EA EA200100051A patent/EA200100051A1/ru unknown
- 1999-07-01 TR TR2001/00133T patent/TR200100133T2/xx unknown
- 1999-07-01 HU HU0103020A patent/HUP0103020A3/hu unknown
- 1999-07-01 SK SK70-2001A patent/SK702001A3/sk unknown
- 1999-07-12 PA PA19998477601A patent/PA8477601A1/es unknown
- 1999-07-15 US US09/354,193 patent/US6166011A/en not_active Expired - Fee Related
- 1999-07-16 PE PE1999000722A patent/PE20000867A1/es not_active Application Discontinuation
- 1999-07-19 GT GT199900113A patent/GT199900113A/es unknown
- 1999-07-19 CO CO99045678A patent/CO5080761A1/es unknown
- 1999-07-19 DZ DZ990148A patent/DZ2848A1/xx active
- 1999-07-19 TN TNTNSN99146A patent/TNSN99146A1/fr unknown
- 1999-07-19 MA MA25689A patent/MA26661A1/fr unknown
- 1999-07-19 AR ARP990103543A patent/AR016501A1/es not_active Application Discontinuation
-
2000
- 2000-12-29 IS IS5799A patent/IS5799A/is unknown
-
2001
- 2001-01-09 ZA ZA200100229A patent/ZA200100229B/en unknown
- 2001-01-18 NO NO20010299A patent/NO20010299L/no not_active Application Discontinuation
- 2001-01-19 HR HR20010053A patent/HRP20010053A2/hr not_active Application Discontinuation
- 2001-02-14 BG BG105249A patent/BG105249A/xx unknown
-
2002
- 2002-03-26 HK HK02102302.7A patent/HK1040706A1/zh unknown
-
2003
- 2003-04-01 US US10/404,524 patent/US20040058905A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| HRP20080113T3 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| PE20040590A1 (es) | Composiciones de pirrolotriazina anilina como inhibidores de cinasa | |
| HUP0400828A2 (hu) | Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CO5130004A1 (es) | 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas | |
| ATE302775T1 (de) | Carbolinderivate | |
| HRP20000896B1 (en) | Adenosine derivatives | |
| ATE357142T1 (de) | 7-aminotriazolopyrimidine zur bekämpfung von schadpilzen | |
| ES2193990T3 (es) | Derivados de purina. | |
| CO5021135A1 (es) | Compuestos quimicos | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR019427A1 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion | |
| DK252286A (da) | Amidderivater af quinolin, fremgangsmaade til deres fremstilling og laegemidler indeholdende disse forbindelser | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| ATE346067T1 (de) | Carbolinderivate | |
| CO5080761A1 (es) | Inhibidores de lad fkbp na inhibidores de las fkbp | |
| ES2255190T3 (es) | Compuestos indol 2,3-sustituidos como inhibidores de cox-2. |